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HypertrophyExcessive bAR stimulation is an independent factor in inducing pathological cardiac hypertrophy.
Here, we report miR-145 regulates both expression and localization of GATA6, thereby protecting
the heart against cardiomyocyte hypertrophy induced by isoproterenol (ISO). The protective activity
of miR-145 was associated with down-regulation of ANF, BNP and b-MHC expression, a decreased
rate of protein synthesis, inhibited cardiomyocyte growth and the modulation of several signaling
pathways including ERK1/2, JNK and Akt-GSK3b. The anti-hypertrophic effect was abrogated by
exogenous over-expression of transcription factor GATA6 which was further identiﬁed as a direct
target of miR-145. In addition, GSK3b antagonists, LiCl and TDZD8, restored the nuclear accumula-
tion of GATA6, which was attenuated by miR-145 Finally, we observed a dynamic pattern of miR-
145 expression in ISO-treated NRCMs and in the hearts of TAC mice. Together, our results identify
miR-145 as an important regulator in cardiac hypertrophy.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction pathological hypertrophy in vitro and in vivo [5,6]. The down-Cardiac hypertrophy is a common pathology in many cardiovas-
cular diseases. Long-term, excessive b-adrenergic receptor (bAR)
stimulation is an independent factor in inducing pathological car-
diac hypertrophy [1]. In spite of the wide clinical use of b-receptor
blockers, the mechanisms by which the complex network of signal-
ing pathways downstream of the bAR are regulated require further
study to identify more speciﬁc therapeutic targets [2]. GATA family
transcription factors are important in regulating the development,
differentiation and growth of many cells and tissues [3,4]. They
share a domain consisting of two adjacent zinc ﬁngers that specif-
ically recognizes nucleotide sequence elements that conform to the
consensus 50-(A/T)GATA(A/G)-30 [4]. GATA4 and GATA6 are two
well-established pro-hypertrophic transcription factors. Over-
expression of GATA4 and/or GATA6 has been found to inducestream transcription targets of GATA4 and GATA6 include ANF,
BNP and b-MHC, which are expressed in the fetal heart and are
reactivated in the hypertrophied heart [7]. The continuous and
abundant GATA factor expression in the heart throughout the life-
span implies the existence of a strict regulatory mechanism that
restricts GATA-mediated transcription activation in the normal
heart.
Here, we report a novel mechanism of GATA6 regulation that is
mediated by a small non-coding RNA, miR-145. We demonstrate
that miR-145 attenuates hypertrophy of cardiomyocytes induced
by the bAR agonist isoproterenol (ISO) by suppressing the expres-
sion and nuclear translocation of GATA6. miR-145 suppresses
GATA6 expression by targeting its 30UTR and reduces the nuclear
accumulation of GATA6 through inhibition of the Akt-GSK3b path-
way. Finally, we show that the expression of miR-145 is dynami-
cally regulated in both ISO-treated cardiomyocytes and in the
hearts of mice that have undergone transverse aortic constriction
(TAC). These results suggest a role for miR-145 in protecting the
heart against bAR agonist-induced pathological hypertrophy.
2. Materials and methods
2.1. Mice
Eight- to twelve-week-old male C57BL/6J mice were purchased
from the Animal Center of Yangzhou University (Yangzhou, China)
Table 1
Real-time PCR primer sequences.
Gene Forward primer (50?30) Reverse primer (50?30)
ANF ATGGGCTCCTTCTCCATCAC TCTTCGGTACCGGAAGCTG
BNP TTGGGCAGAAGATAGACCGGAT GGTCTTCCTAAAACAACCTCA
b-MHC GCAGCTTATCAGGAAGGAATAC CTTGCGTACTCTGTCACTC
GAPDH TCTACATGTTCCAGTATGACTC ACTCCACGACATACTCAGCACC
R. Li et al. / FEBS Letters 587 (2013) 1754–1761 1755and maintained in the Animal Laboratory Center of Drum Tower
Hospital (Nanjing, China) on a 12 h light/dark cycle (lights off at
19:00) with food and water available ad libitum. Cardiomyocytes
were obtained from 1-day-old Sprague–Dawley rats purchased
from the Animal Center of Nanjing Medical University (Nanjing,
China). All of the animal experiment protocols were approved by
the Institutional Animal Care and Use Committee of the Afﬁliated
Drum Tower Hospital of Nanjing University Medical School.
2.2. Transverse aortic constriction (TAC)
Thirty-two male C57BL/6J mice were randomly divided into
four groups of eight mice each, as follows: sham 1 wk group, TAC
1 wk group, sham 4 wk group and TAC 4 wk group. Essentially, sur-
gical procedures were performed as previously described [8].
Brieﬂy, a partial ligation (constriction) of the aortic arch was intro-
duced between the right innominate artery and the left common
carotid artery using a 27-gauge needle as a guide. The sham oper-
ation was performed likewise, but the aorta was not ligated. The
success of the procedure was conﬁrmed by measuring both left
ventricle function and the thickness of the inter-ventricular wall
by echocardiography before the animal was sacriﬁced.
2.3. Primary culture of neonatal rat cardiac myocytes (NRCMs)
The generation of a miR-145 adenovirus (Ad-mir-145) and the
isolation of cardiomyocytes from 1-day-old Sprague–Dawley rats
were performed as previously described [9]. Adenoviruses were
used to transduce cells at the indicated multiplicity of infection
(MOI). The cells were further transfected with plasmid constructs
and, at 48 h after transfection, were stimulated for 24 h with
10 lM ISO (Sigma, St. Louis, USA). Lithium chloride (LiCl, Sigma,
St. Louis, USA) was diluted with phosphate buffered saline (PBS)
and added to the cells at a ﬁnal concentration of 10 mM 2 h before
harvesting; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
(TDZD8, Sigma, St. Louis, USA) with dimethyl sulfoxide (DMSO)
and added at concentration of 10 lM, 12 h before harvesting. The
control cells were added with the same volume PBS or DMSO.
2.4. Generation of the GATA6 over-expression construct and
transfection of cardiomyocytes
A plasmid containing the coding sequence of rat GATA6 (NCBI
Reference Sequence: NM_019185) was prepared by cloning the
indicated sequence into the pCMV-FLAG-2 vector (Sigma, St. Louis,
USA). Effectene transfection reagent (Qiagen, Cat. No. 301425) was
used to transfect NRCMs with the plasmid. A rat miR-145 inhibitor
and an miRNA inhibitor control were purchased from RiBo Bio
(Guangzhou, China).
2.5. Luciferase reporter assay
The ﬁreﬂy luciferase cDNA was fused with the rat GATA6 30UTR
(fromNCBI Reference Sequence: NM_019185) containing either the
seed sequence for miR-145 (nucleotides 1602-1609 of the GATA6
cDNA) or a mutated form of this seed sequence (50-AACTCCAA-30)
[10]. The two resulting fusion constructs were cloned into the
pGL3 promoter luciferase reporter vector (Promega, Madison,
USA). Preconﬂuent H9c2 cells were transduced with Ad-LacZ or
Ad-miR-145 for 24 h, and the cells were then transfected with
300 ng of the ﬁreﬂy luciferase reporter plasmid (pGL3-luc-GATA6-
30UTR or pGL3-luc-GATA6-30UTR mut) and 20 ng of the Renilla
luciferase reporter plasmid pRL-RSV (Promega, Madison, USA)
using Lipofectamine 2000 transfection reagent (Invitrogen, Carls-
bad, USA). Cell lysates were assayed for luciferase activity 48 h after
transfection using the Luciferase Assay System (Promega, Madison,USA) according to the manufacturer’s instructions. All of the assays
were performed in duplicate, and three biological replicates were
assayed per condition.
2.6. Quantitative real-time PCR
Total RNAwas extracted from cultured cells using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) in accordance with the manufac-
turer’s instructions. Two micrograms of total RNA were reverse
transcribed in a total volume of 20 ll, using MMLV reverse trans-
criptase kit (Promega,Madison, USA). Real-time PCRwas performed
using SYBR green (Bio-Rad, Hercules, USA) ﬂuorescence to detect
miR-145 expression as previously described [9]. Complementary
DNA was synthesized using a miR-145-speciﬁc stem-loop primer
with the following sequence: 50-CTCAACTGGTGTCGTGGAGTCGG
CAATTCAGTTGAGAGGGATTC-30. The quantitative polymerase chain
reaction was performed using the following primers: forward, 50-
CGCGCTCGAGCCCAGAGCAATAAGCCACAT-30; reverse, 50-GGTGTCG
TGGAGTCGGCAATTCAGTTGAG-30. The primers corresponding to
the small nuclear RNA U6 (U6) gene were: forward, 50-CTCGCTT
CGGCAGCACA-30; reverse, 50-AACGCTTCACGAATTTGCGT-30. The
U6 reverse primer was also used in the reverse transcription of
U6. The PCR conditions used were as follows: 95 C for 15 min, fol-
lowed by 40 cycles of 95 C for 15 s and 60 C for 1 min. The samples
were run in duplicate, and RNA preparations from three indepen-
dent experiments were assayed. Each real-time PCR reaction con-
sisted of 2 ll RT product, 10 ll SYBR Green PCR Master Mix, and
500 nM each of the forward and reverse primers. Reactions were
carried out on aMyiQ Single-Color Real-Time PCR Detection System
(Bio-Rad, Hercules, USA). The fold change in the expression of each
gene was calculated using the 2DDct method with U6 as an internal
control. The primers used to assay the expression of the rat ANF,
BNP, b-MHC and GAPDH genes are listed in Table 1. GAPDH served
as an internal control gene for these assays.
2.7. Western blotting analysis
Total protein lysates were assayed for protein expression using
anti-ANF (Millipore, Billerica, USA), anti-GATA6 (Cell Signaling
Technology, Danvers, USA), anti-ERK, anti-p-ERK (T204/Y202),
anti-JNK, anti-p-JNK (T183), anti-Akt, anti-p-Akt (S473), anti-p-
Akt (T308), anti-mTOR, anti-p-mTOR (S2448), anti-GSK3b, anti-p-
GSK3b (S9), anti-GATA4, anti-p70S6K, anti-p-p70S6K (T389),
anti-Lamin B1, anti-C/EBP-b, anti-p53 and anti-GAPDH (Bioworld,
Dublin, USA) antibodies. Nuclear and cytoplasmic lysates were pre-
pared to evaluate the nuclear translocation of GATA6 and GATA4.
GAPDH served as an internal control in the expression assays per-
formed on the total protein lysates and on the cytoplasmic lysates,
while Lamin B1 served as an internal control in assays performed
on the nuclear lysates.
2.8. Immunoﬂuorescence
Cells were cultured in chambers (Millipore, Billerica, USA) at a
density of 1  105 cells/chamber and transduced with Ad-miR-
145 or Ad-LacZ. Either the miR-145 inhibitor or the control inhib-
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cells were treated with 10 lM ISO. LiCl (10 mM) or TDZD8
(10 lM) were used to treat the cells at 2 or 12 h before harvesting,
respectively. The cells were then ﬁxed in 4% paraformaldehyde and
incubated with anti-alpha-sarcomeric actin (Abcam, Hong Kong)
and/or anti-GATA6 (Cell Signaling Technology, Danvers, USA) anti-
bodies at room temperature for 2 h, after which the cells were
incubated for 1 h with FITC-conjugated goat anti-rabbit antibody
(Millipore, Billerica, USA). The cell nuclei were stained with DAPI
(5 lg/ml). The cells were examined by confocal microscopy.
2.9. S35 cysteine incorporation
The cells were incubated in serum-free DMEM for 12 h before
the addition of 1 lCi/ml [35S]-cysteine (Amersham Bioscience,
USA) in the presence of 10 lM ISO. After a further 12 h incubation,
the cells were washed twice with ice-cold PBS and ﬁxed with
ice-cold 10% TCA (Wako Pure Chemical Industries, Japan). The
TCA-insoluble fraction was resolved with 1 M NaOH, and the
radioactivity of the solution was then determined using a liquid
scintillation counter (Bioscan, Triathler, USA).
2.10. Statistics
All data are presented as the means ± S.E.M. from at least three
independent experiments. Statistical analysis with Student’s t test
was performed using SPSS software. A value of P < 0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. Over-expression of miR-145 inhibited ISO-induced hypertrophy in
cardiomyocytes
In a previous study, we found that miR-145 regulates the mito-
chondrial apoptotic pathway in cardiomyocytes [9]. Additionally,
results from miRNA microarray analysis of healthy people and
end-stage heart failure patients have shown that miR-145 expres-
sion is signiﬁcantly up-regulated in the latter group [12]. These
ﬁndings led us to ask whether miR-145 plays a role in ISO-induced
hypertrophy in cardiomyocytes. We ﬁrst examined miR-145
expression in NRCMs treated with either Ad-miR-145 or the miR-
145 inhibitor. As expected, miR-145 expression increased after
infection with Ad-miR-145 and decreased after transfection of
the miR-145 inhibitor. Both of these effects were dose-dependent
(Fig. 1A). We next examined the effect of miR-145 upon: (1) the
expression of ANF, BNP and b-MHC, (2) the rate of protein synthe-
sis, and (3) cell size. Real-time PCR assays showed that, following
ISO treatment, the levels of transcripts corresponding to the ANF,
BNP and b-MHC genes declined in a dose-dependent manner in
Ad-miR-145-transduced cardiomyocytes compared with Ad-lacZ-
transduced cardiomyocytes, whereas transfection of cells with
the miR-145 inhibitor did not decrease the levels of these tran-
scripts (Fig. 1B). The 35S incorporation assay also identiﬁed a
marked decrease in the rate of protein synthesis in cells transduced
with Ad-miR-145 and treated with ISO as compared with that in
cells treated with ISO alone. Down-regulation of miR-145 by the
miR-145 inhibitor did not affect the high 35S uptake observed in
ISO-treated cardiomyocytes (Fig. 1C). Lastly, confocal microscopy
showed that ISO-treated cells typically presented with enlarged
cytoplasmic regions and strong actin staining. Over-expression of
miR-145 in these cells resulted in reductions in both the size of
the cytoplasmic regions observed and the intensity of the actin
staining. The size of the cells treated with the miR-145 inhibitor
and ISO was comparable to that of the cells treated with ISO alone
(Fig. 1D and E).3.2. miR-145 suppressed ISO-induced cardiomyocyte hypertrophy by
targeting the transcription factor GATA6
Given that miR-145 expression protects cardiomyocytes against
ISO-induced hypertrophy, we next asked how miR-145 functions
in the hypertrophic process and whether it has any direct func-
tional targets. We searched for the predicted targets of miR-145
in the miRDB database (http://mirdb.org/miRDB/) and found that
GATA6 is a potential target for this microRNA (Fig. 2A). Accord-
ingly, we constructed luciferase reporter plasmids containing the
30UTR region of the rat GATA6 gene carrying either an unmutated
or a mutated putative miR-145 binding site (Fig. 2A) [10]. After
overexpression of miR-145 in H9c2 cells, luciferase activity of the
construct carrying the unmutated 3’UTR of GATA6 decreased sig-
niﬁcantly, but the similar effect was not observed with the lucifer-
ase fusion construct carrying the mutated 3’UTR of GATA6 (Fig. 2B).
We performed western blotting analysis to examine the expression
of endogenous GATA6 in NRCMs transduced with Ad-miR145. As
shown in Fig. 2C, over-expression of miR-145 markedly suppressed
endogenous GATA6 expression in a dose-dependent manner in the
absence of ISO, whereas the expression of GATA4 showed no obvi-
ously dose-dependent change (Fig. 2C). Importantly, increasing the
expression of GATA6 in NRCMs (Fig. 2D) in the presence of ISO to-
tally or partially abrogated the effects of miR-145 on fetal gene
expression (Fig. 3A), on the rate of 35S uptake (Fig. 3B), and on cell
size (Fig. 3C and D), which suggests that miR-145 exerts its regula-
tory effects by targeting GATA6.
3.3. miR-145 inhibited the Akt-GSK3b pathway
We next investigated the effects of miR-145 on several impor-
tant hypertrophic signaling pathways. Over-expression of miR-
145 was found to increase the phosphorylation of ERK and JNK at
24 h after ISO stimulation (Fig. 4A). While the phosphorylation of
Akt at T308 was unaffected by miR-145 over-expression, its phos-
phorylation at S473 was signiﬁcantly down-regulated (Fig. 4B). In
addition, the levels of phosphorylation of several pathway compo-
nents downstream of p-Akt (S473), namely the phosphorylation of
mTOR (at S2448), p70S6K (at T389) and GSK3b (at S9), were down-
regulated by miR-145 over-expression when assayed at 24 h after
ISO treatment. The protein level of ANF was also altered by miR-
145 and/or ISO in a manner similar to that observed for p-Akt
(S473) (Fig. 4B). Moreover, we found that the expression levels of
both GATA6 and GATA4 were markedly decreased by miR-145 in
the presence of ISO treatment (Fig. 4B).
3.4. miR-145 attenuated GATA6 nuclear translocation by inhibiting
GSK3b phosphorylation
Given that GATA4 and GATA6 are expressed abundantly in the
heart throughout life, it is likely that their sub-cellular localizations
and transcriptional activities are strictly regulated. Because we
have shown that GATA6 is a functional target of miR-145, we were
interested to know whether miR-145 expression affects the sub-
cellular localization of GATA6 in ISO-treated cardiomyocytes. As
shown in Fig. 5A, ISO stimulation caused nearly all of the GATA6
protein to localize to the nucleus, while overexpression of miR-
145 partly restored the normal cytoplasmic pattern of GATA6
localization. The results of the western blotting further demon-
strated that ISO-induced GATA6 nuclear translocation was signiﬁ-
cantly inhibited by miR-145 (Fig. 5C). In contrast, cells treated with
the miR-145 inhibitor displayed an abnormal nuclear distribution
of GATA6 (Fig. 5A and C).
GSK3b is an important negative regulator of GATA4 transloca-
tion, and we hypothesized that the sub-cellular localization of
GATA6 might also be affected by GSK3b. If so, the inhibition of
Fig. 1. miR-145 inhibited ISO-induced hypertrophy in cultured NRCMs. (A) Stem-loop real time PCR was used to detect changes in miR-145 levels in NRCMs after infected
with Ad-miR-145 or transfected with miR-145 inhibitor at the MOI or nM indicated for 48 h. (B) Quantitative real time PCR was used to measure the expression of the fetal
genes ANF, BNP and b-MHC in cells following the indicated treatments. (C) The rate of 35S uptake was measured using a liquid scintillation counter. (D) Confocal microscopy
images show the changes in cell size in the indicated groups. The scale bar represents 20 lm. (E) The average ratio of cell size to nucleus size was calculated for 50 randomly
chosen cells from each group in (D). The data are presented as the means ± S.E.M. Statistical signiﬁcance was determined by Student’s t test. ⁄, P < 0.05; ⁄⁄, P < 0.01.
Fig. 2. miR-145 targeted the 30UTR of GATA6. (A) The putative binding site for miR-145 in rat GATA6 (upper sequence) and the corresponding mutated seed sequence used in
this study (lower sequence) are shown. (B) Luciferase assays were performed in H9c2 cells using 300 ng pGL3-GATA6-30UTR-Luc or pGL3-GATA6-30UTRmut-Luc. Cells were
transfected with different doses of Ad-miR-145 (+, 50 MOI; ++, 100 MOI). The luciferase activity was normalized for transfection efﬁciency using the corresponding Renilla
luciferase activity. The data are presented as the means ± S.E.M. Statistical signiﬁcance was determined using Student’s t test. ⁄, P < 0.05; ⁄⁄, P < 0.01. (C) Western blotting
analysis of GATA6 and GATA4 expression in total protein lysates of NRCMs transduced with different doses of Ad-miR-145. (D) Western blotting analysis of ﬂag tag and
GATA6 expression in total protein lysates of NRCMs transfected with different doses of pCMV-Flag-GATA6 (0, 0.2, 0.5, 1.0, 2.0 lg). GAPDH served as an internal control.
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Fig. 3. Over-expression of GATA6 abrogated the protective effects of miR-145. (A) Quantitative real time PCR analysis of fetal gene expression in the indicated samples. (B)
The rate of 35S uptake under different experimental conditions is shown. 35S uptake was measured using a liquid scintillation counter. (C) Confocal microscopy images
showing the size of cells in each indicated group. (D) The average ratio of cell size to nucleus size was calculated for 50 cells randomly chosen from different ﬁelds of view. The
data are presented as the means ± S.E.M. Statistical signiﬁcance was determined using Student’s t test. ⁄, P < 0.05; ⁄⁄, P < 0.01.
Fig. 4. miR-145 regulated hypertrophic pathways. Cells were transduced with
gradient doses of Ad-miR-145 (+, 50 MOI; ++, 100 MOI) for 48 h and then treated
with 10 lM ISO for 24 h. (A) Western blotting analysis of the levels of p-ERK, ERK, p-
JNK and JNK in total protein lysates. (B) Western blotting analysis of the levels of
the indicated proteins in total protein lysates. GAPDH served as an internal control
in both experiments.
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explained by miR-145-mediated inhibition of the Akt-GSK3b
pathway. To test this hypothesis, we employed two structurally
different GSK3b inhibitors: lithium chloride (LiCl) and 4-benzyl-
2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD8). Western blot-
ting showed that treatment of cells with LiCl or TDZD8 alone
increased the nuclear localization of GATA6 and GATA4 (Fig. 5D).
Through a combination of confocal microscopy and western
blotting analysis, we found that either LiCl or TDZD8 treatment
abrogated the inhibitory effect of miR-145 on GATA6 nuclear
translocation in the presence of ISO (Fig. 5B and D). These results
suggest that miR-145 attenuates GATA6 nuclear accumulation
through inhibition of GSK3b phosphorylation.
3.5. miR-145 expression was altered in ISO-treated cardiomyocytes
and in TAC mice
To investigate whether the expression level of miR-145 is corre-
lated with cardiomyocyte hypertrophy in vitro and in vivo, we ana-
lyzed the level of mature miR-145 in NRCMs at different time
points after treatment with ISO. The quantitative real-time PCR re-
sults showed that the expression of miR-145 increased in response
to ISO treatment and reached a peak at 4 h following administra-
tion of the drug, after which time it declined gradually to an
approximately basal level (Fig. 6A). The level of GATA6 protein,
as determined by western blotting, was found to be increased dra-
matically at the 8-hour and 12-hour timepoints and was decreasedslightly at 24 h after ISO stimulation (Fig. 6B). We also discovered
elevated miR-145 expression in mice that had undergone the TAC
Fig. 5. miR-145 inhibited the nuclear accumulation of GATA6 through regulation of GSK3b. Cells were transduced with 50 MOI Ad-miR-145 before being treated with 10 lM
ISO for 24 h. Before harvesting, cells were treated with 10 mM LiCl for 2 h or 10 lM TDZD8 for 12 h. The control cells were treated with the same volume PBS and/or DMSO.
(A) and (B) Confocal microscopy images show the sub-cellular localization of GATA6 (red) relative to the nucleus, stained by DAPI (blue), and the cytoplasm, stained by
sarcomeric actin (green). The upper row of panels shows GATA6 staining only. The middle row shows the merged images of GATA6 and DAPI staining, while the lower panels
show the merged GATA6, DAPI and sarcomeric actin images. (C) and (D) Western blotting was performed to detect the levels of GATA4 and GATA6 in the isolated nuclear and
cytoplasmic lysates. Lamin B1 and GAPDH served as internal positive controls for the nuclear and cytoplasmic lysates, respectively.
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(1 week). However, this level had declined by 4 week after TAC to a
level comparable to that found in the sham group (Fig. 6C). Given
that miR-145 was previously shown to be regulated by transcrip-
tion factor p53 and C/EBP-b, we detected both protein levels in
ISO-treated cardiomyocytes. Western blot showed that while p53
was up-regulated and maintained at a high level in response to
ISO stimulation, C/EBP-b was signiﬁcantly up-regulated from 4 to
24 h after ISO was introduced (Fig. 6D). These results provide fur-
ther evidence of a correlation between miR-145 expression and
cardiomyocyte hypertrophy.4. Discussion
microRNAs have been implicated in various physiological and
pathological processes in the cardiovascular system [11]. In the
present study, we have demonstrated that miR-145 regulates
ISO-induced cardiomyocyte hypertrophy by modulating the
expression and localization of the transcription factor GATA6.
Cardiac hypertrophy is a complicated process. While the ﬁnal
stage of hypertrophy is accompanied by compromised cardiomyo-
cyte function, the very ﬁrst stage is often seen as an adaptive strat-
egy in stressed cardiomyocytes. The borderline between
Fig. 6. miR-145 expression was altered in ISO-treated NRCMs and in the cardiac tissues of TAC mice. (A) Stem-loop real time PCR analysis of the expression level of miR-145
in cardiomyocytes (NRCMs) at various time points after treated with 10 lM ISO. (B) Western blotting analysis of the level of GATA6 in whole cell lysates from cells treated
with 10 lM ISO for the indicated time courses. (C) Stem-loop real time PCR analysis of the expression of miR-145 in ventricle tissues from mice at 1 or 4 week after TAC or
sham operation (n = 8 in each group). The data are presented as the means ± S.E.M. Statistical signiﬁcance was determined using Student’s t test. (D) Western blotting analysis
of the levels of p53 and C/EBP-b at different time point after ISO treatment, GAPDH served as internal control. ⁄, P < 0.05; ⁄⁄, P < 0.01.
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ambiguous. A previous genome-wide proﬁling study of miRNAs
in healthy people and in patients with end-stage heart failure
found that miR-145 was signiﬁcantly up-regulated in the latter
group [12]. In our study, we also observed a signiﬁcant elevation
of miR-145 expression in the hearts of mice 1 week after they
had undergone the TAC procedure (Fig. 6C). Based on these ﬁnd-
ings, we have concluded that miR-145 is involved in the regulation
of pathological hypertrophy. However, the mechanisms by which
miR-145 functions in the stages of physiological and pathological
hypertrophy require further investigation through in vivo
experiments.
Although we demonstrated in our study that miR-145 and
GATA6 was both up-regulated at the early stage of ISO stimulation
(Fig. 6A and B), the mechanisms seem to be different. Previous
study identiﬁed that the transcription of miR-145 is positively reg-
ulated by p53 and negatively regulated by C/EBP-b [13,14]. We
found that the protein level of p53 increased during the whole
course of ISO treatment, while that of C/EBP-b elevated only since
4 h after ISO was added. Our result suggests that during the ﬁrst
4 h of ISO stimulation, the positive regulation of miR-145 by p53
dominated the negative regulation by C/EBP-b, resulting in an in-
crease in miR-145 level with a restricted up-regulation of GATA6
(Fig. 6A and B); however in the later stage, the effect of p53
counteracted that of C/EBP-b, thus resulting in a stabilized level
of miR-145 with a dramatically up-regulated GATA6 (Fig. 6A and
B). Nevertheless, the complex mechanisms regarding the dynamic
changes of miR-145 and GATA6 in response to ISO treatment
indeed warrant further studies.
Our results also showed that miR-145 regulates the nuclear
translocation of GATA6 through GSK3b (Fig. 5B and D). GSK3b
has attracted a great deal of attention in the ﬁeld of cardiovascular
research. Studies have shown that it plays cardioprotective roles in
ischemia preconditioning and cardiac hypertrophy [15–17]. Nota-
bly, GSK3b was shown to directly phosphorylate GATA4 and stim-
ulate Crm-1-dependent nuclear export of GATA4 [17]. Crm-1 is aversatile nuclear transport receptor that recognizes the leucine-
rich nuclear export signal (NES) sequence. Earlier reports sug-
gested that phosphorylation of GATA4 by GSK3b exposes the NES
sequence of GATA4 and thus commits the protein to nuclear export
[17]. In the case of rat GATA6, we also found a conserved leucine-
rich amino acid sequence (LPGLPYL) that is very likely to be the
NES sequence. Furthermore, a previous study demonstrated that
the nuclear export of GATA6 also depends upon Crm-1 [18]. These
ﬁndings, coupled with the fact that phosphorylation of GSK3b at
Ser9 and Ser21 typically leads to its inactivation [17], made it rea-
sonable for us to hypothesize that miR-145-mediated attenuation
of the nuclear accumulation of GATA6 is at least partially due to
the ability of miR-145 to inhibit GSK3b phosphorylation. In the
presence of ISO, GSK3b is phosphorylated and inactivated by its
upstream regulator Akt, and the removal of this negative constraint
from GATA transcription factors would likely result in their nuclear
accumulation and activation. In our study, we showed that treat-
ment of cells with LiCl or TDZD8 caused marked nuclear accumu-
lation of GATA6 (Fig. 5A and B); thus, we have veriﬁed that
GSK3b regulates GATA6. However, whether there is a direct pro-
tein-protein interaction between GSK3b and GATA6 and whether
GSK3b phosphorylates GATA6 in a manner similar to GATA4 are
questions that require further research.
Whenwe analyzed the localization of GATA6by confocalmicros-
copy and western blotting, we found that even untreated cardio-
myocytes contain a considerable amount of nuclear GATA6
(Fig. 5A). Although miR-145 expression dramatically reduced the
nuclear levels of GATA6, it only modestly increased the cytoplasmic
level of the protein (Fig. 5A). We hypothesize that this was due to
proteasome-mediated degradation of GATA6 in the cytoplasm. Ear-
lier reports identiﬁeda cAMP-dependent, proteasome-drivenmech-
anism of GATA6 proteolysis that acts upon GATA6 proteins that are
exported from the nucleus [18,19]. This process seems to be acti-
vated by JNK [18]. Consistent with this, we observed an increase in
JNK phosphorylation in response to miR-145 (Fig. 4A). This may be
anothermechanismbywhichmiR-145 regulatesGATA6expression.
R. Li et al. / FEBS Letters 587 (2013) 1754–1761 1761Compared with GATA6, GATA4 has been more intensively stud-
ied in the cardiovascular ﬁeld. For a long time, the apparent ‘‘func-
tional redundancy’’ of GATA4 and GATA6 has kept GATA6 out of
the spotlight [5,6]. However, in recent years, it has been noted that
GATA6 is both necessary and sufﬁcient to regulate the cardiac
hypertrophy process [5]. In our study, we did not observe any nota-
ble changes in GATA4 expression in response to miR-145 alone
(Fig. 2c). Meanwhile, over-expression of GATA6 was sufﬁcient to
offset the anti-hypertrophic effects of miR-145 (Fig. 3A–D). These
observations collectively show that GATA6 is an independent
functional target of miR-145 in ISO-induced cardiomyocyte
hypertrophy.
Long-term bAR stimulation is characterized by activation of the
PI3K-Akt pathway [20]. Two sites of phosphorylation on Akt, T308
and S473, are both linked with bAR stimulation [20]. Selectivity in
the regulation of these two phosphorylated isoforms has only been
reported in a few studies, and the mechanisms of their regulation
remain poorly understood. Agouni et al. reported that, in renal car-
cinoma, the parathyroid hormone-related protein activates inte-
grin-linked kinase (ILK), which then selectively phosphorylates
(or facilitates the phosphorylation of) Ser473 of Akt [21]. Coinci-
dentally, another recent study found that ILK, the key cardiac sen-
sor of hypertrophic stress, is one of the targets of miR-145 [22].
This is consistent with our ﬁnding that miR-145 favors to inhibit
the phosphorylation of Akt at S473 (Fig. 4B). In addition to ILK,
miR-145 might also target other signaling molecules in the PI3K-
Akt pathway, such as p70S6K [10]. The p70S6K protein is thought
to play important roles in cardiac hypertrophy, apoptosis and angi-
ogenesis. In our study, we found that the levels of total p70S6K and
phosphorylated p70S6K were both down-regulated by miR-145
(Fig. 4B). It would therefore be interesting to determine whether
miR-145 is functionally involved in all these processes.
In summary, we identiﬁed a novel post-transcriptional regula-
tory mechanism for bAR agonist-induced cardiomyocyte hypertro-
phy. We also demonstrated a link between GATA6 and the
Akt-GSK3b pathway. The facts that miR-145 modulates multiple
hypertrophic signaling pathways and that its expression level is
dynamically altered during the development of hypertrophy
strongly support the notion that miR-145 is a critical regulator of
cardiomyocyte hypertrophy and encourages further investigation
of the role of miR-145 in physiological and/or pathological hyper-
trophy and the transition between them.
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